Monopar Therapeutics (MNPR) Total Current Liabilities (2016 - 2020)
Monopar Therapeutics (MNPR) has disclosed Total Current Liabilities for 5 consecutive years, with $609840.0 as the latest value for Q3 2020.
- Quarterly Total Current Liabilities rose 26.09% to $609840.0 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $609840.0 through Sep 2020, up 26.09% year-over-year, with the annual reading at $724165.0 for FY2019, 81.24% up from the prior year.
- Total Current Liabilities hit $609840.0 in Q3 2020 for Monopar Therapeutics, up from $573127.0 in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $724165.0 in Q4 2019 to a low of $64510.0 in Q4 2016.
- Historically, Total Current Liabilities has averaged $429542.8 across 5 years, with a median of $443520.0 in 2020.
- Biggest five-year swings in Total Current Liabilities: skyrocketed 383.44% in 2017 and later fell 23.53% in 2020.
- Year by year, Total Current Liabilities stood at $64510.0 in 2016, then surged by 383.44% to $311867.0 in 2017, then rose by 28.12% to $399551.0 in 2018, then soared by 81.24% to $724165.0 in 2019, then fell by 15.79% to $609840.0 in 2020.
- Business Quant data shows Total Current Liabilities for MNPR at $609840.0 in Q3 2020, $573127.0 in Q2 2020, and $443520.0 in Q1 2020.